- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00722215
Endothelin Receptor Antagonism in Proteinuric Nephropathy
The Systemic & Renal Effects of Endothelin Receptor Antagonism in Proteinuric Nephropathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Response to ETA Receptor Antagonism/Nifedipine/Placebo Prior to the study visit subjects will be asked to refrain from alcohol for 24 hours. Tea and coffee will not be permitted for at least 12 hours before each visit. Studies will be conducted in a quiet, temperature-controlled room.
On arrival at the Clinical Research Centre on the study day, a brief medical enquiry and examination will confirm the ongoing suitability of the subject for the study. An intravenous cannula will be inserted into the antecubital fossa of each arm. We have developed a basic protocol described fully in our previous studies that allows us to measure systemic haemodynamics by the well validated technique of bioimpedance and renal function by standard para-aminohippurate (PAH; renal blood flow) and inulin (glomerular filtration rate) clearance studies.
Urinary protein excretion will be measured by collecting urine over 30 minute time periods. To ascertain the contribution of renal haemodynamics to any change in protein excretion renal blood flow and glomerular filtration rate will be measured. In addition, blood and urine will also be assayed for sodium, creatinine and osmolality to allow calculation of fractional excretion of sodium and free water clearance.
Systemic haemodynamic monitoring will be performed at 15 minute intervals during drug/placebo administration and at 30 minute intervals outwith these periods.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH4 2XU
- Clinical Research Centre, Western General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female
- Age 18-70
- Body mass index <35
- Blood pressure <160/110 mmHg
- CKD stage 2-5 as per the K/DOQI classification
- Proteinuria in one of the following categories: 0.3-1.5, >1.5-3.0, and >3.0-6.0 g/24hrs
- Normal serum albumin
Exclusion Criteria:
- Subject is below the age of legal consent, or is mentally or legally incapacitated
- History of multiple and/or severe allergic reactions to drugs (including study drugs), or food
- The subject has donated blood (450 ml) within the last 4 weeks
- Past or present drug or alcohol abuse including intravenous drug abuse at any time
- Participation in another clinical trial within 1 month
- Considered to be at high risk of HIV or hepatitis B
- Pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
Placebo control arm of study
|
Single 15ml 0.9% saline infused for 15 mins as placebo control
|
Experimental: 2
BQ-123 arm of study
|
Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
|
Active Comparator: 3
Nifedipine arm of study
|
Single dose of nifedipine 10 mg given orally as active control
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proteinuria
Time Frame: Acute change in proteinuria over 4 hour period following BQ-123 dosing
|
Acute change in proteinuria over 4 hour period following BQ-123 dosing
|
Blood pressure
Time Frame: Acute change in blood pressure over 4 hour period following BQ-123 dosing
|
Acute change in blood pressure over 4 hour period following BQ-123 dosing
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Arterial stiffness (as measured by pulse wave velocity)
Time Frame: Acute change in arterial stiffness over 4 hour period following BQ-123 dosing
|
Acute change in arterial stiffness over 4 hour period following BQ-123 dosing
|
Endothelial function (as measured by flow-mediated dilatation)
Time Frame: Acute change in endothelial function over 4 hour period following BQ-123 dosing
|
Acute change in endothelial function over 4 hour period following BQ-123 dosing
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Urological Manifestations
- Renal Insufficiency
- Urination Disorders
- Kidney Diseases
- Renal Insufficiency, Chronic
- Proteinuria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Endothelin Receptor Antagonists
- Nifedipine
- Endothelin A Receptor Antagonists
Other Study ID Numbers
- 2006/WCRC/02
- PG/05/91
- 06/MRE00/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proteinuria
-
Universiteit AntwerpenCompleted
-
University of Sao PauloCompleted
-
Nantes University HospitalTerminated
-
Marshall UniversityUniversity at BuffaloRecruiting
-
Greater Boston Medical AssociatesMassachusetts General HospitalUnknownDecrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte FunctionUnited States
-
Gulhane School of MedicineCompletedWe Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria.Turkey
-
University of Mississippi Medical CenterCompletedPregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) | Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) | Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)United States
-
Zekai Tahir Burak Women's Health Research and Education...UnknownBasal Proteinuria in PregnancyTurkey
-
Brigham and Women's HospitalBristol-Myers SquibbCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Unknown
Clinical Trials on 0.9 % saline
-
Tri-Service General HospitalCompleted
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
University of California, DavisEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedDiabetic Ketoacidosis | Cerebral EdemaUnited States
-
Rigshospitalet, DenmarkCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
University of MalayaUnknown
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Coronary Disease | Neurologic ManifestationsUnited States
-
Santaris Pharma A/SCompleted
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
CSL BehringTerminatedOral MucositisUnited States, Canada, Australia, Germany, Italy, Austria